

Production of Radioisotopes in the BR2 Reactor :


Past Performances and Future Prospects

Bernard Ponsard

Head of the "RSP Unit"


Radioisotopes and NTD-Silicon Production


bponsard@sckcen.be



PONSARD B.
Copyright © 2016
SCK•CEN

- Introduction
- The BR2 High-Flux Reactor
- Radioisotopes for Diagnosis
 - ^{99}Mo supply
 - $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ by fission
- Radioisotopes for Therapy and Palliation
 - ^{177}Lu , $^{188}\text{W}/^{188}\text{Re}$, $^{117\text{m}}\text{Sn}$, ^{153}Sm , ^{89}Sr , ^{192}Ir , ^{90}Y , ...
- Radioisotopes for Industrial applications
 - ^{192}Ir , ^{75}Se , ^{203}Hg , ...
- Conclusions





PONSARD B.
Copyright © 2016
SCK•CEN

- The **BR2 reactor** is a multipurpose **100 MW_{th}** High-Flux 'Materials Testing Reactor' operated since 1961 (first criticality) by the Belgian Nuclear Research Centre (SCK•CEN) to perform various **research** (materials, fuel) and **commercial** programs.
- The commercial activities such as **radioisotope production** and **silicon doping** have been actively developed since the early 1990's to generate additional revenues and **to reduce BR2's financial dependence** on Government funding.
- An important maintenance program is in place to operate the BR2 reactor on a **safe and reliable way**. The beryllium matrix of the reactor has been replaced in the period February 2015 – June 2016 to provide an operating lifetime extension **until 2026**, at least.

The BR2 Reactor



PONSARD B.
Copyright © 2016
SCK•CEN

Reactor type

- High Flux Materials Testing Reactor
- Pressurized, light water
- Be matrix, compact core
- HEU fuel (93% ^{235}U)
- LEU conversion project in place
- In operation since 1963
- Refurbishments:

1979-1980 _ 1995-1997 _ 2015-2016


Aluminium pressure vessel

- Geometry : hyperboloid of revolution
- Easy access to the top and bottom
- Diameter : 1 to 2 m
- Height : 8.6 m


Very compact core

- Diameter : 1.05 m
- Height : 0.91 m


100 MW



02/2012.A4




Unique shape



Typical configuration

PONSARD B.
Copyright © 2016
SCK•CEN


The BR2 Reactor




- **Operating power** : 55 – 100 MW_{th}
- **Operating cycle** : 21 – 28 days
- **Operating regime** : 6 cycles per year, i.e. 190 days per year
- **Moderators** : Beryllium and Light water
- **Primary coolant** : Light water @ 12 bars
- **Water temperature** : 40 - 45 °C
- **Flow rate** : 6 500 m³/h
- **Fuel** : HEU (Highly Enriched Uranium); 93% U-235
- **Control rods** : Hafnium
- **Neutron fluxes** :
 - **Thermal ($E_n < 0.5$ eV)** : up to 1.0×10^{15} n/cm².s
 - **Epithermal ($E_n \sim 5$ eV)** : up to 4.2×10^{13} n/cm².s
 - **Fast ($E_n > 100$ keV)** : up to 6.0×10^{14} n/cm².s

The BR2 Reactor

BR2 REACTOR



- The BR2 reactor is a major player in the production of radioisotopes worldwide:
 - High neutron fluxes (thermal up to $e+15\text{ n/cm}^2.\text{s}$ and fast up to $6\text{ e}+14\text{ n/cm}^2.\text{s}$), large irradiation volumes, very flexible, ... but limited by its operating regime (140 – 190 operating days per year).



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m



**Mo-99/Tc-99m
Generator**

PONSARD B.
Copyright © 2016
SCK•CEN

- The worldwide supply of Mo-99 relies on a **limited number** of research reactors and processing facilities.
- Its production is **essential for nuclear medicine** as Tc-99m, obtained from Mo-99/Tc-99m generators, is used in about **80% of diagnostic** nuclear imaging procedures.
- These applications represent approximately **30 million** examinations worldwide per year.
- Therefore, a weekly Mo-99 production of about **9.000 Ci '6-day'** calibrated is required to supply **North America** (53%), **Europe** (23%), **Asia** (20%) and the **rest of the world** (4%).
- Given the short half-lives of Mo-99 (66 hours) and its daughter Tc-99m (6 hours), a **regular supply of Mo-99/Tc-99m** generators to hospitals or central radiopharmacies is required.

Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m




PONSARD B.

Copyright © 2016
SCK·CEN

- The **supply chain** consists of :
 - uranium **target manufacturers**
 - **research reactors** for target irradiation
 - **processing facilities** to dissolve the irradiated targets and extract Mo-99
 - Mo-99/Tc-99m **generators manufacturers**
 - **radiopharmacies** to elute Tc-99m from the generators and prepare radiopharmaceutical doses to be injected to the patients for diagnosis
 - **transport companies** to ship the produced activities to the different participants involved in the supply chain.

From the producers to the users ... No time to lose ...



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m



**Targets
manufacture**



**BR2
Reactor**

**Targets
irradiation**



Targets shipment



Mo-99/Tc-99m



Targets processing



PONSARD B.
Copyright © 2016
SCK•CEN

Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

OPERATIONS INVOLVED	TIME SCALE	EVOLUTION OF THE MO-99 ACTIVITY
IRRADIATION IN THE REACTOR	150 HOURS	1000 Ci Mo-99 'EOI' / target
UNLOADING FROM THE REACTOR ...	12 HOURS	
LOADING CONTAINERS	4 HOURS	
SHIPMENT CONTAINERS	4 HOURS	810 Ci / target
PROCESSING IRRADIATED TARGETS	12 HOURS	640 Ci bulk Mo-99
SHIPMENT BULK Mo-99	12 HOURS	
MANUFACTURE and DELIVERY GENERATORS	12 HOURS	500 Ci Mo-99
USE IN HOSPITALS	120 HOURS	120 Ci Mo-99 '6-DAY'


Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

The “6-day Ci” is a unit of measure that takes the Mo-99 decay rate into account, the losses during shipments and processing, and represents an average amount of Mo-99 that would be available for use 6 days after processing

Mo-99 Global Demand


About 9.000 Ci Mo-99 ‘6-day’ calibrated per week !!!

Or about 468.000 Ci Mo-99 ‘6-days’ calibrated per year !!!



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

- BR2 has the **largest irradiation capacity** in the world for the production of Mo-99 !!!
- The **6 PRF** (Primary Reloadable water-cooled device for Fissile targets) **irradiation devices** are routinely loaded in BR2 reflector channels.
- They provide a total simultaneous irradiation capacity of **75 HEU targets**.
- These targets are cooled by the **primary reactor water** and loaded/unloaded during the reactor operation.
- Irradiation capacity = **65%** of the global Mo-99 demand in peak, i.e. **25%** in average.





Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235




To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Targets unloading





Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235



To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235



To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235



To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235



To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235



To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m

From U-235




To Mo-99

PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m



PONSARD B.
Copyright © 2016
SCK·CEN

- The BR2 reactor is member of the **AIPES** Reactors & Isotopes Working Group which has the task to secure the global supply of Mo-99.
 - **Ten reactors** are represented in the AIPES R&I WG: **BR2** (Belgium), **HFR** (Netherlands), **SAFARI** (South Africa), **MARIA** (Poland), **LVR-15** (Czech Republic), **OPAL** (Australia), **RA-3** (Argentina), **FRM-II** (Germany; currently not irradiating targets for Mo-99), **NRU** (Canada; no routine production from November 2016), **OSIRIS** (France; shutdown) and **JHR** (France; under construction).
 - **Six processors** are represented in the AIPES R&I WG: **IRE** (Belgium), **MALLINCKRODT** (NL), **ANSTO Health** (Australia), **NTP** (South Africa), **CNEA** (Argentina) and **CNL/NORDION** (Canada; no routine production from November 2016).


Radioisotopes for Diagnosis: Production of Mo-99/Tc-99m



PONSARD B.
Copyright © 2016
SCK•CEN




"VERSAILLES Mo-99 MODEL" Maximum Global Mo-99 Reactor Production Capacity per week




Radioisotopes for Therapy and Palliation: Production of Lu-177, Sm-153, ...

- The **BR2 Reactor** is not only producing Mo-99.
- **Dedicated irradiation devices** allow the routine production of various radioisotopes for **therapy** and **palliation treatments**:
 - I-131 and Xe-133 in the PRF irradiation devices (... Mo-99)
 - Ir-192, Sr-89, W-188/Re-188, ... in RA25 irradiation baskets
 - Lu-177, Re-186, Sm-153, Er-169, Y-90, ...in DG thimbles
 - Sn-117m, Cu-67, ... in RH15 irradiation baskets
- Currently, SCK is **not performing any chemical process** on target material irradiated in the BR2 reactor in the frame of the production of radiopharmaceuticals.
- **Special efforts** are expected to be made in the near future by SCK to develop the production of new radioisotopes, including **chemical processing** for some of those.



Radioisotopes for Therapy and Palliation: Production of Lu-177, Sm-153, ...



PONSARD B.

Copyright © 2016

SCK·CEN

- The BR2 reactor is routinely producing **Ir-192** ($T_{1/2}=74.2$ d), for curietherapy and several radioisotopes for metastatic bone pain palliation as **Re-186** ($T_{1/2}=3.8$ d), **Sm-153** ($T_{1/2}=46.7$ h), **Y-90** ($T_{1/2}=64$ h) and **Sr-89** ($T_{1/2}=50.5$ d).
- The BR2 reactor is also routinely producing the very attractive **Lu-177** ($T_{1/2}=6.7$ d) for targeted therapy of small tumours (prostate, ...) and metastatic bone pain palliation by both direct and indirect routes.
 - **Direct route:** $^{176}\text{Lu} (n_{\text{th}}, \gamma) ^{177}\text{Lu}$; yield = 35 Ci/mg at “EOI”
 - **Indirect route:** $^{176}\text{Yb} (n_{\text{th}}, \gamma) ^{177}\text{Yb} \rightarrow ^{177}\text{Lu}$;
yield = 110 Ci/mg at “EOI”
- Furthermore, reactor operators have collaborated on several occasions to secure the supply of additional radioisotopes that have become more interesting such as **W-188/Re-188** and **Sn-117m** ($T_{1/2}=13.6$ d), especially with the HFIR reactor at Oak Ridge National Laboratory (ORNL, USA).

Radioisotopes for Industrial Applications: Production of Ir-192, ...




PONSARD B.
Copyright © 2016
SCK·CEN

- The BR2 reactor is **not only** producing medical radioisotopes.
- BR2 is a major producer of **Ir-192** worldwide.
- **Ir-192** is one of the most widely used sealed sources for Non Destructive Testing (NDT) applications and is produced by $^{191}\text{Ir}(n,\gamma)^{192}\text{Ir}$ reaction on natural or Ir-191 enriched iridium discs.
- **Ir-192** decays with a half-life of **74.2 days** to stable Pt-192 and emits **beta particles** at a maximum energy of 672 keV (46%) and **gamma rays** at energies of 604, 468 and 308 keV.
- BR2 is able to achieve high Ir-192 specific activities in the range of **500** to **1500 Ci/g at “EOI”** in a full cycle irradiation of 21 to 28 days.




Radioisotopes for Industrial Applications: Production of Ir-192, ...



PONSARD B.
Copyright © 2016
SCK•CEN



Radioisotopes for Industrial Applications: Production of Ir-192, ...



PONSARD B.
Copyright © 2016
SCK•CEN




Shipment
Container

10 kCi ^{192}Ir



Radioisotopes for Industrial Applications: Production of Se-75, ...



- The production of **Se-75** (γ rays : 66 – 401 keV) – in complementarity to Ir-192 (γ rays : 308 – 604 keV) – for NDT applications is under development.
- Several irradiations have been already performed in the BR2 reactor and provided **encouraging results**.
- The availability of **very high thermal neutron fluxes** (in the range of $e+15$ n/cm².s) and the use of highly (98%) **enriched Se-74** target material (very high cost price) are mandatory for this kind of production.
- **Se-75** versus Ir-192 has **several advantages** as increased contrast and image quality, lesser radiation for users, softer gamma rays, smaller steel wall thickness investigations, ...

Conclusions

- The **BR2 reactor** is a **major facility** for the global production of radioisotopes for nuclear medicine and industry.
- Serious efforts have been made to perform all BR2's commercial activities (production of 'Radioisotopes' and 'Neutron Transmutation Doped Silicon') in accordance with a '**Quality System**' that has been certified to the requirements of the "**EN ISO 9001: 2008** – Quality Systems – Model for **Quality Assurance** in production, installation and servicing".
- The production of several new radioisotopes is currently investigated as the β^- emitters **Ho-166** and **Y-90** microspheres for liver cancer treatment.
- The production of radioisotopes for **alpha therapy** is also under investigation (**Ra-223**, ...).



Copyright © 2016 - SCK•CEN

All property rights and copyright are reserved.

Any communication or reproduction of this document, and any communication or use of its content without explicit authorization is prohibited. Any infringement to this rule is illegal and entitles to claim damages from the infringer, without prejudice to any other right in case of granting a patent or registration in the field of intellectual property.

SCK•CEN

Studiecentrum voor Kernenergie
Centre d'Etude de l'Energie Nucléaire

Stichting van Openbaar Nut
Fondation d'Utilité Publique
Foundation of Public Utility

Registered Office: Avenue Herrmann-Debrouxlaan 40 – BE-1160 BRUSSEL
Operational Office: Boeretang 200 – BE-2400 MOL